We will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.
|Original language||English (US)|
|Journal||ONCOLOGY (United States)|
|State||Published - May 15 2016|
ASJC Scopus subject areas
- Cancer Research